Showing 4 posts of 4 posts found.


Takeda’s subcutaneous vedolizumab nabs CHMP nod for maintenance of ulcerative colitis and Crohn’s

February 28, 2020
Medical Communications, Sales and Marketing CHMP, EMA, Takeda, vedolizumab

Takeda’s subcutaneous formulation of its gut-selective biologic vedolizumab has secured recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal …

Takeda’s subcutaneous vedolizumab proves efficacious in Phase III trial for Ulcerative Colitis

October 22, 2018
Sales and Marketing Takeda, UC, biologic, phase III, results, ulcerative colitis, vedolizumab

Japanese pharma firm Takeda has announced that the gut-selective biologic vedolizumab when taken as a subcutaneous (SC) injection, proved efficacious …

Takeda HQ, Tokyo image

Takeda gets NICE nod for bowel treatment

March 13, 2015
Sales and Marketing NHS, NICE, Takeda, enyyvio, vedolizumab

Takeda’s Entyvio becomes the first NICE approved gut-selective treatment for UK patients with ulcerative colitis (UC) – a long-term condition …

Entyvio image

NICE rejects Takeda Crohn’s disease drug

December 23, 2014
Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab

Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …

Latest content